P0DTC2 (SPIKE_SARS2) Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
Spike glycoprotein UniProtKBInterProInteractive Modelling
1273 aa; Sequence (Fasta) Identical sequences: Severe acute respiratory syndrome coronavirus 2: A0A679G9E9; A0A6G7K2L4
Molecule Processing
| Spike protein S1 | |
| Spike protein S2 | |
| Spike protein S2' |
It is possible new templates exist for this target since these models were created.
Sequence Features
| 614 | D -> G (common polymorphism; Produces more infectious particles when pseudotyped on VSV ex vivo;) | ||
| 1214-1234 | Helical | ||
| 685-686 | Cleavage; by TMPRSS2 or furin | ||
| 815-816 | Cleavage; by host | ||
| 15-136 | |||
| 131-166 | |||
| 291-301 | |||
| 336-361 | |||
| 379-432 | |||
| 391-525 | |||
| 480-488 | |||
| 538-590 | |||
| 617-649 | |||
| 662-671 | |||
| 738-760 | |||
| 743-749 | |||
| 840-851 | |||
| 1032-1043 | |||
| 1082-1126 | |||
| 33-337 | Betacoronavirus-like spike glycoprotein S1, N-terminal IPR032500PF16451 | ||
| 349-526 | Spike receptor binding domain, betacoronavirus IPR018548PF09408 | ||
| 536-592 | Coronavirus spike glycoprotein S1, C-terminal IPR043607PF19209 | ||
| 711-1232 | Spike glycoprotein S2, coronavirus IPR002552PF01601 |
Sequence Alignments
Experimental structures
| Description | Oligo-state | Ligands | Structure | Range |
|---|---|---|---|---|
| S-2H2-F2 structure, two RBDs are up and one RBD is down, each up RBD binds with a 2H2 Fab. |
Heteromer | 7dk6 | ||
| Assess | ||||
| S-3C1-F1 structure, one RBD is up and two RBDs are down, the up RBD binds with a 3C1 fab |
Heteromer | 7dd8 | ||
| Assess | ||||
| S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab. |
Heteromer | 7dcx | ||
| Assess | ||||
| S-2H2-F1 structure, one RBD is up and two RBDs are down, only up RBD binds with a 2H2 Fab |
Heteromer | 7dk5 | ||
| Assess | ||||
| S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab. |
Heteromer | 7dk4 | ||
| Assess | ||||
| S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab. |
Heteromer | 7dk7 | ||
| Assess | ||||
| S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with… |
Heteromer | 7dcc | ||
| Assess | ||||
| S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab. |
Heteromer | 7dd2 | ||
| Assess | ||||
| SARS-CoV-2 S trimer, S-open |
Heteromer | 14×GLN; 21×PRO; 21×ARG; 33×THR; 11×CYS; 36×LEU; 24×LYS; 37×ASN; 32×VAL; 22×ALA; 26×TYR; 23×GLY; 22×ASP; 36×PHE; 35×SER; 6×HIS; 6×TRP; 23×ILE; 16×GLU; 2×MET; | 7dk3 | |
| Assess | ||||
| P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein |
Heteromer | 15×NAG; 16×NAG; | 7cwn | |
| Assess | ||||
| SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail |
Heteromer | 15×NAG; 16×NAG; | 7cws | |
| Assess | ||||
| SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail |
Heteromer | 15×NAG; 16×NAG; | 7cwu | |
| Assess | ||||
| Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed st… |
Heteromer | 14×NAG; 16×NAG; | 7cwm | |
| Assess | ||||
| SARS-CoV-2 S-ACE2 complex |
Heteromer Q9BYF1; | 18×NAG; 36×NAG; | 7df4 | |
| Assess | ||||
| S protein of SARS-CoV-2 in complex bound with 4A8 |
Heteromer | 6×NAG; 23×NAG; 25×NAG; | 7c2l | |
| Assess | ||||
| SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Clockwise Direction |
Heteromer Q9BYF1; | 7a95 | ||
| Assess | ||||
| SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Anticlockwise Direction |
Heteromer Q9BYF1; | 7a96 | ||
| Assess | ||||
| SARS-CoV-2 Spike Glycoprotein with 2 ACE2 Bound |
Heteromer Q9BYF1; | 7a97 | ||
| Assess | ||||
| SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound |
Heteromer Q9BYF1; | 23×NAG; 1×ZN; | 7a94 | |
| Assess | ||||
| SARS-CoV-2 Spike Glycoprotein with 3 ACE2 Bound |
Heteromer Q9BYF1; | 7a98 | ||
| Assess | ||||
| Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing nanobodies (Ty1) |
Heteromer | 12×NAG; 39×NAG; | 6zxn | |
| Assess | ||||
| SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment |
Heteromer | 12×NAG; 3×NAG; 36×NAG; | 7jw0 | |
| Assess | ||||
| Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) 2-up confor… |
Heteromer | 8×NAG; 45×NAG; | 7a29 | |
| Assess | ||||
| Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) |
Heteromer | 9×NAG; 45×NAG; | 7a25 | |
| Assess | ||||
| SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment |
Heteromer | 18×NAG; 3×NAG; 30×NAG; | 7k43 | |
| Assess | ||||
| SARS-CoV-2 spike in complex with LCB1 (2RBDs open) |
Heteromer | 13×NAG; 33×NAG; | 7jzl | |
| Assess | ||||
| Cryo-EM structure of double ACE2-bound SARS-CoV-2 trimer Spike at pH 7.4 |
Heteromer Q9BYF1; | 4×NAG; 53×NAG; | 7kmz | |
| Assess | ||||
| Cryo-EM structure of triple ACE2-bound SARS-CoV-2 trimer spike at pH 7.4 |
Heteromer Q9BYF1; | 8×NAG; 55×NAG; | 7kms | |
| Assess | ||||
| Cryo-EM Structure of Double ACE2-Bound SARS-CoV-2 Trimer Spike at pH 5.5 |
Heteromer Q9BYF1; | 4×NAG; 48×NAG; | 7knh | |
| Assess | ||||
| Cryo-EM structure of Triple ACE2-bound SARS-CoV-2 Trimer Spike at pH 5.5 |
Heteromer Q9BYF1; | 6×NAG; 56×NAG; | 7kni | |
| Assess | ||||
| SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab |
Heteromer | 15×NAG; 30×NAG; | 7cak | |
| Assess | ||||
| SARS-CoV-2 S trimer with two RBDs in the open state and complexed with two H014 Fab |
Heteromer | 15×NAG; 30×NAG; | 7cai | |
| Assess | ||||
| Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 7.4 |
Heteromer Q9BYF1; | 5×NAG; 46×NAG; | 7knb | |
| Assess | ||||
| Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 5.5 |
Heteromer Q9BYF1; | 6×NAG; 44×NAG; | 7kne | |
| Assess | ||||
| SARS-CoV-2 spike in prefusion state |
Heteromer | 16×NAG; 4×NAG; 7×NAG; 18×NAG; 2×MAN; 3×DMS; | 6zow | |
| Assess | ||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab f… |
Heteromer | 9×NAG; 1×NAG; 2×NAG; 1×NAG; 30×NAG; | 6xcm | |
| Assess | ||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab f… |
Heteromer | 9×NAG; 3×NAG; 3×NAG; 24×NAG; | 6xcn | |
| Assess | ||||
| Cryo-EM Structure of SARS-CoV-2 Spike : H11-D4 Nanobody Complex |
Heteromer | 20×NAG; 26×NAG; | 6z43 | |
| Assess | ||||
| SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab |
Heteromer | 13×NAG; 23×NAG; | 6zdh | |
| Assess | ||||
| SARS CoV2 Spike ectodomain with engineered trimerized VH binder |
Heteromer | 7jwb | ||
| Assess | ||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 13×NAG; 34×NAG; | 7k8w | |
| Assess | ||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 15×NAG; 27×NAG; | 7k8s | |
| Assess | ||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 13×NAG; 1×NAG; 1×NAG; 33×NAG; | 7k8z | |
| Assess | ||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 10×NAG; 21×NAG; | 7k8v | |
| Assess | ||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 15×NAG; 30×NAG; | 7k8t | |
| Assess | ||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 1×NAG; 2×NAG; | 7k8u | |
| Assess | ||||
| SARS-CoV-2 Spike in complex with neutralizing nanobody mNb6 |
Heteromer | 18×NAG; 27×NAG; | 7kkl | |
| Assess | ||||
| SARS-CoV-2 Spike Glycoprotein with one ACE2 Bound |
Heteromer Q9BYF1; | 17×NAG; 36×NAG; | 7kj2 | |
| Assess | ||||
| SARS-CoV-2 Spike Glycoprotein with two ACE2 Bound |
Heteromer Q9BYF1; | 20×NAG; 40×NAG; | 7kj3 | |
| Assess | ||||
| SARS-CoV-2 Spike Glycoprotein with three ACE2 Bound |
Heteromer Q9BYF1; | 24×NAG; 42×NAG; | 7kj4 | |
| Assess | ||||
| SARS-CoV-2 Spike in complex with neutralizing nanobody Nb6 |
Heteromer | 12×NAG; 30×NAG; | 7kkk | |
| Assess | ||||
| Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to two copies of domain-swapped antibody 2G12 |
Heteromer | 8×NAG; 2×NAG; 2×NAG; 2×NAG; 25×NAG; | 7l06 | |
| Assess | ||||
| Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound domain-swapped antibody 2G12 from masked 3D r… |
Heteromer | 10×NAG; 1×NAG; 1×NAG; 1×NAG; 32×NAG; | 7l09 | |
| Assess | ||||
| Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to one copy of domain-swapped antibody 2G12 |
Heteromer | 10×NAG; 1×NAG; 1×NAG; 1×NAG; 31×NAG; | 7l02 | |
| Assess | ||||
| H11-H4 bound to Spike |
Heteromer | 20×NAG; 26×NAG; | 6zhd | |
| Assess | ||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 28×NAG; | 7k8x | |
| Assess | ||||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 23×NAG; | 7k8y | |
| Assess | ||||
| BD23-Fab in complex with the S ectodomain trimer |
Heteromer | 5×NAG; 1×NAG; 32×NAG; | 7byr | |
| Assess | ||||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs |
Heteromer | 5×NAG; 31×NAG; | 7chh | |
| Assess | ||||
| SARS-CoV-2 spike in complex with LCB3 (2RBDs open) |
Heteromer | 13×NAG; 33×NAG; | 7jzn | |
| Assess | ||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 33×NAG; | 7k90 | |
| Assess | ||||
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-4 |
Heteromer | 7×NAG; 3×NAG; 2×NAG; 36×NAG; | 6xey | |
| Assess | ||||
| S protein of SARS-CoV-2 in complex bound with T-ACE2 |
Heteromer Q9BYF1; | 35×NAG; 34×NAG; | 7ct5 | |
| Assess | ||||
| SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment |
Heteromer | 15×NAG; 33×NAG; | 7k4n | |
| Assess | ||||
| SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open) |
Heteromer | 11×NAG; 36×NAG; | 7jv4 | |
| Assess | ||||
| SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation) |
Heteromer | 12×NAG; 36×NAG; | 7jv6 | |
| Assess | ||||
| SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment |
Heteromer | 12×NAG; 3×NAG; 33×NAG; | 7jvc | |
| Assess | ||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the ACE2 protein decoy, CTC-445.2 (State 4) |
Heteromer | 2×NAG; 27×NAG; | 7kl9 | |
| Assess | ||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab f… |
Heteromer | 12×NAG; 3×NAG; 33×NAG; | 6wps | |
| Assess | ||||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab f… |
Heteromer | 10×NAG; 1×NAG; 1×NAG; 35×NAG; | 6wpt | |
| Assess | ||||
| Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Unmasked Refinement) |
Heteromer Q9BYF1; | 1×NAG; 7×NAG; 1×ZN; | 7a92 | |
| Assess | ||||
| Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement) |
Heteromer | 2×NAG; | 7a5s | |
| Assess | ||||
| Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement) |
Heteromer | 2×NAG; | 7a5r | |
| Assess | ||||
| Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer Q9BYF1; | 1×NAG; 7×NAG; 1×ZN; | 7a91 | |
| Assess | ||||
| Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a potent neutralizing… |
Heteromer | 1×NAG; | 6xe1 | |
| Assess | ||||
| Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab |
Heteromer | 8×DMS; 5×MLI; 2×NAG; 1×1PE; | 6yla | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.3 |
Heteromer | 1×NAG; | 6xc4 | |
| Assess | ||||
| Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by st… |
Heteromer | 1×NAG; | 7jx3 | |
| Assess | ||||
| H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex |
Heteromer | 1×NAG; | 6z2m | |
| Assess | ||||
| Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A … |
Heteromer | 1×NAG; 1×PO4; | 6zer | |
| Assess | ||||
| Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal for… |
Heteromer | 6ym0 | ||
| Assess | ||||
| Soaking competent crystal form of the SARS-CoV-2 Receptor Binding Domain (RBD):CR3022 complex. |
Heteromer | 1×NAG; | 6zlr | |
| Assess | ||||
| Structure of SARS-CoV-2 spike receptor-binding domain complexed with high affinity ACE2 mutant 3N39 |
Heteromer Q9BYF1; | 2×NAG; 2×NAG; 1×NAG; 1×NAG; 1×ZN; 1×SO4; | 7dmu | |
| Assess | ||||
| H11-D4 complex with SARS-CoV-2 RBD |
Heteromer | 1×NAG; 12×EDO; 4×ACT; | 6yz5 | |
| Assess | ||||
| Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody |
Heteromer | 1×NAG; | 7bz5 | |
| Assess | ||||
| H11-H4 complex with SARS-CoV-2 |
Heteromer | 1×NAG; 1×SO4; | 6zbp | |
| Assess | ||||
| Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab) |
Heteromer | 1×NAG; | 7kfv | |
| Assess | ||||
| Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-F10 Fab) |
Heteromer | 1×NAG; | 7kfy | |
| Assess | ||||
| Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-C2 Fab) |
Heteromer | 1×NAG; | 7kfx | |
| Assess | ||||
| Structure of novel coronavirus spike receptor-binding domain complexed with its receptor ACE2 |
Heteromer Q9BYF1; | 4×NAG; 1×ZN; | 6lzg | |
| Assess | ||||
| Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex wi… |
Heteromer | 1×NAG; 5×CL; 1×MG; | 6zcz | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022 |
Heteromer | 1×NAG; | 6xc3 | |
| Assess | ||||
| Structure of sybody MR17 in complex with the SARS-CoV-2 S receptor-binding domain (RBD) |
Heteromer | 1×NAG; 1×GOL; | 7c8w | |
| Assess | ||||
| Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab) |
Heteromer | 1×NAG; | 7kfw | |
| Assess | ||||
| Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD |
Heteromer | 1×NAG; | 7c01 | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022 |
Heteromer | 1×NAG; | 6xc7 | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with cross-neutral… |
Heteromer | 1×NAG; | 7jmw | |
| Assess | ||||
| Structure of sybody MR17-K99Y in complex with the SARS-CoV-2 S Receptor-binding domain (RBD) |
Heteromer | 1×NAG; 1×GOL; | 7can | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutra… |
Heteromer | 1×NAG; | 7k9z | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody CR3022 |
Heteromer | 1×GOL; 2×SO4; 1×NAG; | 6w41 | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.1 |
Heteromer | 1×NAG; | 6xc2 | |
| Assess | ||||
| H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex |
Heteromer | 1×NAG; | 6yz7 | |
| Assess | ||||
| Ternary complex CR3022 H11-H4 and RBD (SARS-CoV-2) |
Heteromer | 6zh9 | ||
| Assess | ||||
| Structure of the SARS-CoV-2 spike S1 protein in complex with CR3022 Fab |
Heteromer | 6yor | ||
| Assess | ||||
| Cryo-EM structure of cat ACE2 and SARS-CoV-2 RBD |
Heteromer Q56H28; | 1×ZN; | 7c8d | |
| Assess | ||||
| SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment (local refinement of t… |
Heteromer | 1×NAG; | 7jva | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab |
Heteromer | 1×NAG; | 7cjf | |
| Assess | ||||
| Structure of sybody SR4 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD) |
Heteromer | 8×GOL; 1×NAG; | 7c8v | |
| Assess | ||||
| Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab |
Heteromer | 1×NAG; | 7chb | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with ACE2 |
Heteromer Q9BYF1; | 1×ZN; 1×CL; 5×NAG; | 6m0j | |
| Assess | ||||
| Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab |
Heteromer | 7chf | ||
| Assess | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-… |
Heteromer | 1×NAG; 5×SO4; | 6xkp | |
| Assess | ||||
| crystal structure of SARS-CoV-2 antibody with RBD |
Heteromer | 1×NAG; | 7bwj | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD |
Heteromer | 1×NAG; | 7cdi | |
| Assess | ||||
| Crystal structure of the SARS-CoV-2 spike receptor-binding domain (RBD) with nanobody Nb20 |
Heteromer | 2×CAC; | 7jvb | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD |
Heteromer | 1×NAG; | 7cdj | |
| Assess | ||||
| Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab |
Heteromer | 7che | ||
| Assess | ||||
| Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab |
Heteromer | 1×NAG; | 6zfo | |
| Assess | ||||
| Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies |
Heteromer | 1×NAG; | 6xdg | |
| Assess | ||||
| Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A … |
Heteromer | 3×NAG; | 6zdg | |
| Assess | ||||
| The interface of H014 Fab binds to SARS-CoV-2 S |
Heteromer | 7cah | ||
| Assess | ||||
| SARS-CoV-2 spike in complex with LCB3 (local refinement of the RBD and LCB3) |
Heteromer | 1×NAG; | 7jzm | |
| Assess | ||||
| SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment (local refinement of … |
Heteromer | 1×NAG; | 7k45 | |
| Assess | ||||
| SARS-CoV-2 spike protein RBD and P17 fab complex |
Heteromer | 7cwo | ||
| Assess | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2… |
Heteromer | 1×NAG; | 7jmo | |
| Assess | ||||
| Crystal structure of the SARS-CoV-2 S RBD in complex with BD-604 Fab |
Heteromer | 7ch4 | ||
| Assess | ||||
| SARS-CoV-2 spike in complex with LCB1 (local refinement of the RBD and LCB1) |
Heteromer | 1×NAG; | 7jzu | |
| Assess | ||||
| ACE2-RBD Focused Refinement Using Symmetry Expansion of Applied C3 for Triple ACE2-bound SARS-CoV-2… |
Heteromer Q9BYF1; | 2×NAG; 5×NAG; | 7kmb | |
| Assess | ||||
| Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody… |
Heteromer | 1×NAG; | 7k8m | |
| Assess | ||||
| Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab |
Heteromer | 7ch5 | ||
| Assess | ||||
| Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab |
Heteromer | 7chc | ||
| Assess | ||||
| The 2019-nCoV RBD/ACE2-B0AT1 complex |
Heteromer Q695T7; Q9BYF1; | 14×NAG; 2×NAG; 10×NAG; 2×LEU; 2×ZN; | 6m17 | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2… |
Heteromer | 1×NAG; | 7jmp | |
| Assess | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-… |
Heteromer | 2×NAG; | 6xkq | |
| Assess | ||||
| Structure of SARS-CoV-2 chimeric receptor-binding domain complexed with its receptor human ACE2 |
Heteromer P59594; Q9BYF1; | 3×NAG; 2×NAG; 1×ZN; 1×CL; 1×EDO; 1×NAG; | 6vw1 | |
| Assess | ||||
| SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody Fab fragment (local refinement of … |
Heteromer | 7jv2 | ||
| Assess | ||||
| Crystal structure of neuropilin-1 b1 domain in complex with SARS-CoV-2 S1 C-end rule (CendR) peptide |
Heteromer O14786; | 1×PEG; | 7jjc | |
| Assess | ||||
| Structure of SARS-CoV-2 3Q-2P full-length dimers of spike trimers | homo-6-mer | 76×NAG; 2×NAG; 2×NAG; 16×NAG; | 7jjj | |
| Assess | ||||
| Structure of the 2019-nCoV HR2 Domain | homo-4-mer | 6lvn | ||
| Assess | ||||
| Distinct conformational states of SARS-CoV-2 spike protein | homo-3-mer | 21×NAG; 9×NAG; 3×NAG; 3×NAG; 21×NAG; | 6xr8 | |
| Assess | ||||
| SARS-Cov2 S protein at close state | homo-3-mer | 7ddd | ||
| Assess | ||||
| SARS-Cov2 S protein at open state | homo-3-mer | 7ddn | ||
| Assess | ||||
| SARS-CoV-2 S trimer, S-closed | homo-3-mer | 24×NAG; 30×NAG; | 7df3 | |
| Assess | ||||
| Furin Cleaved Spike Protein of SARS-CoV-2 with One RBD Erect | homo-3-mer | 6zgg | ||
| Assess | ||||
| Furin Cleaved Spike Protein of SARS-CoV-2 in Intermediate Conformation | homo-3-mer | 6zgh | ||
| Assess | ||||
| Furin Cleaved Spike Protein of SARS-CoV-2 in Closed Conformation | homo-3-mer | 27×NAG; 24×NAG; | 6zgi | |
| Assess | ||||
| Uncleavable Spike Protein of SARS-CoV-2 in Closed Conformation | homo-3-mer | 30×NAG; 21×NAG; | 6zge | |
| Assess | ||||
| Structure of SARS-CoV-2 3Q-2P full-length prefusion spike trimer (C3 symmetry) | homo-3-mer | 45×NAG; 3×NAG; 3×VCG; 3×EIC; | 7jji | |
| Assess | ||||
| SARS-CoV-2 Spike Glycoprotein with 2 RBDs Erect | homo-3-mer | 7a93 | ||
| Assess | ||||
| Structure of SARS-CoV-2 Spike Protein Trimer (K986P, V987P, single Arg S1/S2 cleavage site) in Lock… | homo-3-mer | 12×NAG; 39×NAG; 3×EIC; | 6zp2 | |
| Assess | ||||
| Structure of Disulphide-stabilized SARS-CoV-2 Spike Protein Trimer (x1 disulphide-bond mutant, S383… | homo-3-mer | 12×NAG; 39×NAG; | 6zoz | |
| Assess | ||||
| Cryo-EM structure of a biotinylated SARS-CoV-2 spike probe in the prefusion state (RBDs down) | homo-3-mer | 12×NAG; 36×NAG; | 6xf5 | |
| Assess | ||||
| Cryo-EM structure of SARS-CoV-2 Spike Proteins on intact virions: 3 Closed RBDs | homo-3-mer | 15×NAG; 33×NAG; | 6zwv | |
| Assess | ||||
| SARS CoV-2 Spike protein, Closed conformation, C3 symmetry | homo-3-mer | 3×NAG; 20×NAG; 3×EIC; | 6zb5 | |
| Assess | ||||
| SARS CoV-2 Spike protein, Closed conformation, C1 symmetry | homo-3-mer | 1×NAG; 25×NAG; 3×EIC; | 6zb4 | |
| Assess | ||||
| Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody | homo-3-mer | 15×NAG; 30×NAG; | 7cab | |
| Assess | ||||
| SARS-CoV-2 spike in prefusion state (flexibility analysis, 1-up closed conformation) | homo-3-mer | 16×NAG; 4×NAG; 7×NAG; 18×NAG; 2×MAN; 3×DMS; | 6zp5 | |
| Assess | ||||
| SARS-CoV-2 spike in prefusion state (flexibility analysis, 1-up open conformation) | homo-3-mer | 16×NAG; 4×NAG; 7×NAG; 18×NAG; 2×MAN; 3×DMS; | 6zp7 | |
| Assess | ||||
| Structure of the prefusion SARS-CoV-2 spike glycoprotein | homo-3-mer | 11×NAG; 27×NAG; | 6z97 | |
| Assess | ||||
| SARS-CoV-2 spike ectodomain structure (open state) | homo-3-mer | 12×NAG; 35×NAG; | 6vyb | |
| Assess | ||||
| SARS-CoV-2 u1S2q All Down RBD State Spike Protein Trimer | homo-3-mer | 6x2c | ||
| Assess | ||||
| Structure of SARS-CoV-2 Spike Protein Trimer (single Arg S1/S2 cleavage site) in Closed State | homo-3-mer | 12×NAG; 36×NAG; | 6zp0 | |
| Assess | ||||
| Consensus structure of SARS-CoV-2 spike at pH 5.5 | homo-3-mer | 14×NAG; 28×NAG; | 6xm0 | |
| Assess | ||||
| SARS-CoV-2 u1S2q 2 RBD Up Spike Protein Trimer | homo-3-mer | 6x2b | ||
| Assess | ||||
| Structure of the SARS-CoV-2 spike glycoprotein (closed state) | homo-3-mer | 15×NAG; 33×NAG; | 6vxx | |
| Assess | ||||
| Structure of SARS-CoV-2 spike at pH 5.5, all RBDs down | homo-3-mer | 16×NAG; 26×NAG; | 6xm5 | |
| Assess | ||||
| Structure of SARS-CoV-2 spike at pH 5.5, single RBD up, conformation 1 | homo-3-mer | 17×NAG; 26×NAG; | 6xm3 | |
| Assess | ||||
| SARS-CoV-2 u1S2q 1 Up RBD Spike Protein Trimer | homo-3-mer | 6x2a | ||
| Assess | ||||
| Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic A… | homo-3-mer | 12×NAG; 33×NAG; | 6x6p | |
| Assess | ||||
| Structure of SARS-CoV-2 spike at pH 4.0 | homo-3-mer | 15×NAG; 32×NAG; | 6xlu | |
| Assess | ||||
| Structure of SARS-CoV-2 spike at pH 5.5, single RBD up, conformation 2 | homo-3-mer | 18×NAG; 25×NAG; | 6xm4 | |
| Assess | ||||
| SARS-CoV-2 rS2d Down State Spike Protein Trimer | homo-3-mer | 6x29 | ||
| Assess | ||||
| Cryo-EM structure of a biotinylated SARS-CoV-2 spike probe in the prefusion state (1 RBD up) | homo-3-mer | 12×NAG; 35×NAG; | 6xf6 | |
| Assess | ||||
| SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA… | homo-3-mer | 15×NAG; 33×NAG; | 7ke8 | |
| Assess | ||||
| Cryo-EM structure of a prefusion stabilized SARS-CoV-2 Spike (D614N, R682S, R685G, A892P, A942P and… | homo-3-mer | 3×NAG; 15×NAG; | 7a4n | |
| Assess | ||||
| SARS-CoV-2 D614G 1-RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-… | homo-3-mer | 12×NAG; 35×NAG; | 7kdl | |
| Assess | ||||
| SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer fully cleaved by furin without the P986-P987 stabi… | homo-3-mer | 15×NAG; 33×NAG; | 7kdi | |
| Assess | ||||
| SARS-CoV-2 D614G 1RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D… | homo-3-mer | 12×NAG; 35×NAG; | 7keb | |
| Assess | ||||
| SARS-CoV-2 RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS) | homo-3-mer | 58×NAG; | 7kdh | |
| Assess | ||||
| SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA… | homo-3-mer | 15×NAG; 33×NAG; | 7ke4 | |
| Assess | ||||
| SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA… | homo-3-mer | 15×NAG; 33×NAG; | 7kdk | |
| Assess | ||||
| SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-… | homo-3-mer | 12×NAG; 34×NAG; | 7kea | |
| Assess | ||||
| SARS-CoV-2 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS) | homo-3-mer | 15×NAG; 33×NAG; | 7kdg | |
| Assess | ||||
| SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer fully cleaved by furin without the P986-P987 stabili… | homo-3-mer | 12×NAG; 35×NAG; | 7kdj | |
| Assess | ||||
| Cryo-EM structure of a prefusion stabilized SARS-CoV-2 Spike (D614N, R682S, R685G, A892P, A942P and… | homo-3-mer | 10×NAG; 10×NAG; | 7ad1 | |
| Assess | ||||
| SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA… | homo-3-mer | 15×NAG; 33×NAG; | 7ke6 | |
| Assess | ||||
| SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-… | homo-3-mer | 12×NAG; 35×NAG; | 7ke9 | |
| Assess | ||||
| SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-… | homo-3-mer | 12×NAG; 33×NAG; | 7kec | |
| Assess | ||||
| SARS-CoV-2 D614G 3-RBD-down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA… | homo-3-mer | 15×NAG; 33×NAG; | 7ke7 | |
| Assess | ||||
| SARS-CoV-2 Spike Glycoprotein, prefusion with one RBD up conformation | homo-3-mer | 12×NAG; 35×NAG; | 7kj5 | |
| Assess | ||||
| Structure of SARS-CoV-2 spike at pH 4.5 | homo-3-mer | 17×NAG; 30×NAG; | 7jwy | |
| Assess | ||||
| SARS-CoV-2 HexaPro S One RBD up | homo-3-mer | 11×NAG; 28×NAG; | 6xkl | |
| Assess | ||||
| Prefusion 2019-nCoV spike glycoprotein with a single receptor-binding domain up | homo-3-mer | 17×NAG; 27×NAG; | 6vsb | |
| Assess | ||||
| Structure of SARS-CoV-2 Spike Protein Trimer (K986P, V987P, single Arg S1/S2 cleavage site) in Clos… | homo-3-mer | 15×NAG; 33×NAG; | 6zp1 | |
| Assess | ||||
| Structure of Disulphide-stabilized SARS-CoV-2 Spike Protein Trimer (x2 disulphide-bond mutant, G413… | homo-3-mer | 15×NAG; 33×NAG; | 6zox | |
| Assess | ||||
| Prefusion SARS-CoV-2 S ectodomain trimer covalently stabilized in the closed conformation | homo-3-mer | 9×NAG; 33×NAG; | 6x79 | |
| Assess | ||||
| Structure of Disulphide-stabilized SARS-CoV-2 Spike Protein Trimer (x1 disulphide-bond mutant, S383… | homo-3-mer | 12×NAG; 36×NAG; | 6zoy | |
| Assess | ||||
| Cryo-EM structure of SARS-CoV-2 Spike ectodomain | homo-3-mer | 8×NAG; 1×NAG; 2×NAG; 2×NAG; 23×NAG; | 7cn9 | |
| Assess | ||||
| SARS-CoV-2 Spike D614G variant, minus RBD | homo-3-mer | 6xs6 | ||
| Assess | ||||
| Distinct conformational states of SARS-CoV-2 spike protein | homo-3-mer | 6×NAG; 6×NAG; 3×NAG; 9×NAG; 3×MAN; | 6xra | |
| Assess | ||||
| Structure of post fusion core of 2019-nCoV S2 subunit | homo-3-mer | 2×PG4; 4×ZN; | 6lxt | |
| Assess | ||||
| Crystal structure of post fusion core of 2019-nCoV S2 subunit | homo-3-mer | 6m1v | ||
| Assess | ||||
Homology models
| Oligo-state | QMEAN | Template | Range | Seq id (%) | Ligands |
|---|---|---|---|---|---|
|
Heteromer Q9BYF1; | -0.23 | 6m0j.1.B | 100.00 | 1×ZN; | |
| Assess | |||||
|
Heteromer Q9BYF1; | -0.45 | 6lzg.1.B | 100.00 | 1×NAG; 1×ZN; | |
| Assess | |||||
|
Heteromer Q9BYF1; | -0.69 | 6vw1.2.B | 96.19 | 1×EDO; | |
| Assess | |||||
|
Heteromer Q9BYF1; | -1.95 | 7a94.1.A | 99.89 | 7×NAG; 1×ZN; | |
| Assess | |||||
|
Heteromer Q9BYF1; | -3.98 | 6acg.1.A | 84.55 | ||
| Assess | |||||